Olema Pharmaceuticals Inc at Credit Suisse Healthcare Conference Transcript
Okay, let's get going. Good morning, my name is Rich Law. I'm a Senior Biotech Analyst at CS. I'd like to welcome our next session Olema for this fireside chat. We're joined by Sean Bohen, President and CEO of Olema. So, Sean, welcome.
Thank you, Rich.
Before we go into the Q&A, any opening remarks that you want to give?
Sure, I mean I think Olema is a women's cancer-focused company. We have a research pipeline as well as our single current clinical asset, which is OP-1250. It's a complete estrogen receptor antagonist and SERD for ER+ breast cancer. And that program has progressed really nicely.
We just presented our updated Phase 1b data and dose selection at ENA in Barcelona. We will at San Antonio. The titles are out. We will present our palbo
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
